Diagnosis: Stage 4 Chronic Kidney Disease (CKD G4)
This patient has Stage 4 CKD with a race-free eGFR of 19-23 mL/min/1.73 m², requiring immediate nephrology referral, preparation for kidney replacement therapy, and initiation of guideline-directed medical therapy including SGLT2 inhibitors if not already started.
CKD Staging and Race-Free eGFR
The 2022 NKF-ASN Task Force recommends abandoning race-based eGFR calculations and using a unified approach without race specification 1. Both values (19 and 23 mL/min/1.73 m²) fall within Stage 4 CKD (eGFR 15-29 mL/min/1.73 m²), indicating severely reduced kidney function regardless of race.
- The race multiplier historically inflated eGFR values in African Americans, potentially delaying appropriate care including transplant referrals 2
- Using the lower value (19 mL/min/1.73 m²) is clinically prudent and aligns with current equity-focused guidelines
BUN/Creatinine Ratio Interpretation
The BUN/Cr ratio of 22.4 is within normal range (10-20 is typical, up to 25 acceptable), suggesting:
- No significant prerenal azotemia (which would show ratio >30)
- No acute interstitial nephritis (which typically shows ratio ≤12) 3
- This represents intrinsic chronic kidney disease rather than acute reversible dysfunction
The elevated absolute BUN (74 mg/dL) and creatinine (3.3 mg/dL) with a proportional ratio indicates advanced CKD with accumulation of both uremic toxins. While elevated BUN/Cr ratios predict worse outcomes in heart failure patients 4, 5, this patient's normal ratio suggests the kidney dysfunction is chronic and intrinsic rather than hemodynamically mediated.
Immediate Management Priorities
1. Nephrology Referral (Urgent)
- eGFR <20 mL/min/1.73 m² triggers transplant evaluation eligibility 2
- Preparation for kidney replacement therapy planning
- Vascular access assessment if hemodialysis anticipated
2. SGLT2 Inhibitor Therapy
Continue or initiate SGLT2i even at this low eGFR 6:
- KDIGO 2024 recommends SGLT2i for eGFR ≥20 mL/min/1.73 m² (1A recommendation)
- Once initiated, continue even if eGFR falls below 20 unless KRT started 6
- Provides mortality and kidney protection benefits
3. RAS Inhibitor Management
Continue ACE inhibitor or ARB 6:
- KDIGO 2024 explicitly states: "Continue ACEi or ARB even when eGFR falls below 30 ml/min per 1.73 m²" (Practice Point 3.6.7)
- Only reduce/discontinue if:
- Symptomatic hypotension
- Uncontrolled hyperkalemia despite treatment
- To reduce uremic symptoms at eGFR <15 6
4. Mineralocorticoid Receptor Antagonist Consideration
Do NOT initiate nonsteroidal MRA at this eGFR:
- KDIGO recommends MRA only for eGFR >25 mL/min/1.73 m² 6
- This patient at 19-23 mL/min/1.73 m² is below the threshold
5. Monitor for Complications
- Hyperkalemia risk: Close monitoring with RASi continuation
- Metabolic acidosis: Check bicarbonate levels
- Anemia of CKD: Check hemoglobin, iron studies, consider ESA
- Bone mineral disease: Check calcium, phosphorus, PTH, vitamin D
- Volume status: Assess for fluid overload requiring diuretics
Key Clinical Pitfalls
- Do not stop SGLT2i or RASi based solely on low eGFR—these medications provide mortality benefit even at advanced stages 6
- Do not use race-based eGFR for clinical decisions—this delays appropriate care in African American patients 1, 2
- Do not assume reversibility based on BUN/Cr ratio—this normal ratio with severely elevated absolute values indicates chronic intrinsic disease, not prerenal azotemia
- Do not delay transplant evaluation—patients with eGFR ≤20 should begin accumulating waitlist time 2